Sunny's Carboprost Tromethamine Injection Granted Saudi FDA Approval
Sunny has successfully obtained regulatory approval and the Abbreviated New Drug Application (ANDA) from the Saudi FDA for its generic Carboprost Tromethamine Injection, indicated for gynecological treatment. This marketing authorization also represents a significant breakthrough, serving as Sunny’s first approval in the Middle East region since the implementation of its "One Product, Multi-Market Approvals" strategy three years ago.